GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carmat (STU:CXT) » Definitions » Institutional Ownership

Carmat (STU:CXT) Institutional Ownership : 1.11% (As of Mar. 05, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Carmat Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Carmat's institutional ownership is 1.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Carmat's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Carmat's Float Percentage Of Total Shares Outstanding is 0.00%.


Carmat Institutional Ownership Historical Data

The historical data trend for Carmat's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carmat Institutional Ownership Chart

Carmat Historical Data

The historical data trend for Carmat can be seen below:

2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31
Institutional Ownership 1.31 1.32 1.30 1.28 1.26 0.94 1.15 1.09 1.11 1.11

Carmat Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Carmat Business Description

Traded in Other Exchanges
Address
36, avenue de l’Europe, Immeuble l’Etendard Energy III, Velizy Villacoublay, FRA, 78140
Carmat is a France-based company engaged in the development and production of heart prosthesis. It engages in the development of implantable orthotopic and biocompatible artificial heart organs for the treatment of heart failure patients. The company also develops the product's power supply system and its control and remote diagnosis systems.